Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

Alopecia areata mainly affects young people and has significant psychological impacts, especially in males.

The document says current treatments for alopecia areata do not cure or prevent it, and it's hard to judge their effectiveness due to spontaneous remission and lack of studies.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Dermoscopy helps diagnose and manage alopecia areata by showing specific hair changes.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

Alopecia areata in these mice is inherited, more common in young females, and can be treated with triamcinolone acetonide.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Current treatments for alopecia show no significant long-term benefits.

Alopecia areata is caused by the immune system attacking hair follicles.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Scalp dermoscopy is good for diagnosing a type of hair loss and helps choose the best spots for biopsy.

Baricitinib was effective in treating alopecia areata in two major trials.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

Topical sensitizers have mixed success in treating alopecia areata.

Skin grafts on mice can cause an immune response leading to hair loss, useful for studying human hair loss conditions.

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

Tofacitinib may help treat severe hair loss, but more research is needed.

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

Cytotoxic T cells cause hair loss in chronic alopecia areata.

A 300 mg monthly pulse of prednisolone effectively and safely treats widespread alopecia areata.

The new clobetasol propionate foam is effective and safe for treating alopecia areata.